Moderna recently expanded its collaboration with Benchling, enhancing its digital infrastructure to foster research innovation. Despite this positive development, Moderna's share price fell 6% over the past month. This decline occurred amid broader market gains, with major U.S. indexes like the Nasdaq and S&P 500 climbing due to optimism around U.S.-UK trade deals and rising cryptocurrency prices. However, Moderna's report of decreased revenues and a significant net loss in Q1 2025 earnings likely added pressure on its share price, counterbalancing broader market trends and highlighting company-specific challenges. Buy, Hold or Sell Moderna? View our complete analysis and fair value estimate and you decide.NasdaqGS:MRNA Earnings Per Share Growth as at May 2025 The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent collaboration between Moderna and Benchling could have significant implications for the company's long-term growth outlook. By enhancing its digital infrastructure, Moderna aims to bolster research innovation, potentially translating into more efficient R&D processes and faster product development cycles. This may positively impact future revenue streams and could improve earnings forecasts by adding new products to its pipeline more expediently. Over the past five years, Moderna's total return, including share price and dividends, has dropped 63.09%, reflecting substantial challenges the company faced in maintaining investor confidence amid a competitive biotechnology sector. In contrast, over the past year, the company's shares underperformed the US Biotechs industry, which saw a 13.5% decline, indicating company-specific difficulties that may not solely be aligned with industry trends. The current share price of Moderna, at US$24.43, is considerably below the consensus analyst price target of US$46.96. This suggests that there is potential upside, assuming the market aligns with the analysts' expectations of improved profitability and growth driven by the mRESVIA approvals and oncology advancements. However, with existing challenges like decreased revenues and high operating costs, it is crucial for investors to consider these hurdles alongside the optimistic projections. Gain insights into Moderna's past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include NasdaqGS:MRNA. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Moderna (NasdaqGS:MRNA) Expands AI-Ready Collaboration With Benchling For R&D Transformation
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...